ES2330408T3 - Polimerizacion activada por pirofosforolisis (pap): aplicacion en la amplificacion de un alelo especifico y en la determinacion de secuencias de acidos nucleicos. - Google Patents
Polimerizacion activada por pirofosforolisis (pap): aplicacion en la amplificacion de un alelo especifico y en la determinacion de secuencias de acidos nucleicos. Download PDFInfo
- Publication number
- ES2330408T3 ES2330408T3 ES01912883T ES01912883T ES2330408T3 ES 2330408 T3 ES2330408 T3 ES 2330408T3 ES 01912883 T ES01912883 T ES 01912883T ES 01912883 T ES01912883 T ES 01912883T ES 2330408 T3 ES2330408 T3 ES 2330408T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- chain
- oligonucleotide
- terminal
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 88
- 238000006116 polymerization reaction Methods 0.000 title claims abstract description 59
- 230000003321 amplification Effects 0.000 title claims description 84
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 84
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 220
- 238000000034 method Methods 0.000 claims abstract description 79
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 68
- 239000002773 nucleotide Substances 0.000 claims abstract description 67
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 50
- 230000000295 complement effect Effects 0.000 claims abstract description 46
- 235000011178 triphosphate Nutrition 0.000 claims abstract description 43
- 239000001226 triphosphate Substances 0.000 claims abstract description 43
- 102000004190 Enzymes Human genes 0.000 claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 24
- 239000002777 nucleoside Substances 0.000 claims abstract description 21
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract description 19
- -1 nucleoside triphosphates Chemical class 0.000 claims abstract description 17
- 235000011180 diphosphates Nutrition 0.000 claims abstract description 16
- 230000001841 pyrophosphorolytic effect Effects 0.000 claims abstract description 16
- 239000011541 reaction mixture Substances 0.000 claims abstract description 8
- 108700028369 Alleles Proteins 0.000 claims description 89
- 108020004414 DNA Proteins 0.000 claims description 75
- 239000005546 dideoxynucleotide Substances 0.000 claims description 64
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 49
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 49
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 24
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 230000013011 mating Effects 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 108010006785 Taq Polymerase Proteins 0.000 claims description 14
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 11
- 238000010348 incorporation Methods 0.000 claims description 11
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 9
- 239000000975 dye Substances 0.000 claims description 8
- 230000008030 elimination Effects 0.000 claims description 8
- 238000003379 elimination reaction Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 7
- RAJMXAZJKUGYGW-POYBYMJQSA-N 2',3'-dideoxycytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)CC1 RAJMXAZJKUGYGW-POYBYMJQSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- PUSXDQXVJDGIBK-NKWVEPMBSA-N [(2s,5r)-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](COP(O)(O)=O)O1 PUSXDQXVJDGIBK-NKWVEPMBSA-N 0.000 claims description 5
- WVNRRNJFRREKAR-JGVFFNPUSA-N 2',3'-dideoxythymidine-5'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)CC1 WVNRRNJFRREKAR-JGVFFNPUSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000037429 base substitution Effects 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000000379 polymerizing effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 238000001962 electrophoresis Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 238000000211 autoradiogram Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108060002716 Exonuclease Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 102000013165 exonuclease Human genes 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000009609 Pyrophosphatases Human genes 0.000 description 5
- 108010009413 Pyrophosphatases Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241001200922 Gagata Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18431500P | 2000-02-23 | 2000-02-23 | |
| US184315P | 2000-02-23 | ||
| US18703500P | 2000-03-06 | 2000-03-06 | |
| US187035P | 2000-03-06 | ||
| US23718000P | 2000-10-03 | 2000-10-03 | |
| US237180P | 2009-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2330408T3 true ES2330408T3 (es) | 2009-12-10 |
Family
ID=27391815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01912883T Expired - Lifetime ES2330408T3 (es) | 2000-02-23 | 2001-02-22 | Polimerizacion activada por pirofosforolisis (pap): aplicacion en la amplificacion de un alelo especifico y en la determinacion de secuencias de acidos nucleicos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6534269B2 (enExample) |
| EP (2) | EP1259646B1 (enExample) |
| JP (1) | JP4989004B2 (enExample) |
| AT (1) | ATE441726T1 (enExample) |
| AU (2) | AU4162101A (enExample) |
| CA (1) | CA2395391C (enExample) |
| DE (1) | DE60139762D1 (enExample) |
| ES (1) | ES2330408T3 (enExample) |
| WO (1) | WO2001062975A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7033763B2 (en) * | 2000-02-23 | 2006-04-25 | City Of Hope | Pyrophosphorolysis activated polymerization (PAP) |
| AUPR050700A0 (en) * | 2000-10-03 | 2000-10-26 | Id+Plus Ltd | Detection method |
| AU2001291513B2 (en) * | 2000-10-03 | 2007-06-07 | Id+Plus Ltd | Nucleotide detection method |
| WO2002044425A2 (en) * | 2000-12-01 | 2002-06-06 | Visigen Biotechnologies, Inc. | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity |
| CA2442169A1 (en) * | 2001-03-30 | 2002-10-10 | Applera Corporation | Nucleic acid analysis using non-templated nucleotide addition |
| GB0110501D0 (en) | 2001-04-30 | 2001-06-20 | Secr Defence Brit | Amplification process |
| US7141370B2 (en) * | 2001-07-03 | 2006-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Bioluminescence regenerative cycle (BRC) for nucleic acid quantification |
| US7668697B2 (en) * | 2006-02-06 | 2010-02-23 | Andrei Volkov | Method for analyzing dynamic detectable events at the single molecule level |
| EP2292787B1 (en) * | 2002-05-10 | 2017-03-22 | City of Hope | Pyrophosphorolysis activated polymerization (PAP) |
| EP1753873A4 (en) | 2004-03-05 | 2008-11-05 | Ohio Med College | METHOD AND COMPOSITIONS FOR THE ASSESSMENT OF NUCLEIC ACIDS AND ALLELES |
| WO2005106036A2 (en) | 2004-04-12 | 2005-11-10 | Medical College Of Ohio | Methods and compositions for assaying analytes |
| US7745125B2 (en) * | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
| US20060060977A1 (en) * | 2004-09-22 | 2006-03-23 | Kabushiki Kaisha Toshiba | Semiconductor device |
| US7378260B2 (en) * | 2005-04-01 | 2008-05-27 | Applera Corporation | Products and methods for reducing dye artifacts |
| JP5596554B2 (ja) * | 2007-11-28 | 2014-09-24 | エフ．ホフマン−ラ ロシュ アーゲー | 向上したピロリン酸分解活性化重合（ｐａｐ）能力を有する変異ｄｎａポリメラーゼ |
| EP2644707B1 (en) | 2008-04-30 | 2015-06-03 | Integrated Dna Technologies, Inc. | RNase-H-based assays utilizing modified RNA monomers |
| US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| CN101381766B (zh) * | 2008-06-11 | 2012-04-18 | 厦门大学 | 一种基因稀有突变的定量检测方法 |
| US20100112565A1 (en) * | 2008-11-03 | 2010-05-06 | Life Technologies Corporation | Methods, kits, and reaction mixtures for high resolution melt genotyping |
| US8481685B2 (en) * | 2008-11-03 | 2013-07-09 | Kapa Biosystems | Modified DNA polymerases |
| US8932813B2 (en) | 2010-12-13 | 2015-01-13 | Life Technologies Corporation | Polymerization of nucleic acids using activation by polyphosphorolysis (APP) reactions |
| WO2012135053A2 (en) | 2011-03-25 | 2012-10-04 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| US10270033B2 (en) | 2015-10-26 | 2019-04-23 | Oti Lumionics Inc. | Method for patterning a coating on a surface and device including a patterned coating |
| CN105316421B (zh) * | 2015-12-01 | 2019-09-03 | 湖南宏雅基因技术有限公司 | 用于检测与肺癌相关的shox2基因启动子区甲基化程度的试剂盒 |
| CN105331727B (zh) * | 2015-12-01 | 2019-09-03 | 湖南宏雅基因技术有限公司 | 一种人外周血循环肿瘤DNA中septin 9基因甲基化的检测试剂盒 |
| WO2018100559A1 (en) | 2016-12-02 | 2018-06-07 | Oti Lumionics Inc. | Device including a conductive coating disposed over emissive regions and method therefor |
| JP2020518107A (ja) | 2017-04-26 | 2020-06-18 | オーティーアイ ルミオニクス インコーポレーテッドＯｔｉ Ｌｕｍｉｏｎｉｃｓ Ｉｎｃ． | 表面上のコーティングをパターン化する方法およびパターン化されたコーティングを含むデバイス |
| KR102685809B1 (ko) | 2017-05-17 | 2024-07-18 | 오티아이 루미오닉스 인크. | 패턴화 코팅 위에 전도성 코팅을 선택적으로 증착시키는 방법 및 전도성 코팅을 포함하는 디바이스 |
| US11655497B2 (en) | 2017-09-26 | 2023-05-23 | Ningbo Shining Biotechnology Co., Ltd | Method of amplifying a target nucleic acid |
| US11751415B2 (en) | 2018-02-02 | 2023-09-05 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
| WO2019180137A1 (en) | 2018-03-21 | 2019-09-26 | F. Hoffmann-La Roche Ag | Dna polymerases for efficient and effective incorporation of methylated-dntps |
| KR20250150689A (ko) | 2018-05-07 | 2025-10-20 | 오티아이 루미오닉스 인크. | 보조 전극을 제공하는 방법 및 보조 전극을 포함하는 장치 |
| US11268140B2 (en) * | 2018-06-12 | 2022-03-08 | Shaofeng Ding | Delayed pyrophosphorolysis activated polymerization |
| CN112889162A (zh) | 2018-11-23 | 2021-06-01 | Oti照明公司 | 包括光透射区域的光电装置 |
| WO2020178804A1 (en) | 2019-03-07 | 2020-09-10 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
| KR20250110358A (ko) | 2019-04-18 | 2025-07-18 | 오티아이 루미오닉스 인크. | 핵 생성 억제 코팅 형성용 물질 및 이를 포함하는 디바이스 |
| US12069938B2 (en) | 2019-05-08 | 2024-08-20 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
| KR20240134240A (ko) | 2019-06-26 | 2024-09-06 | 오티아이 루미오닉스 인크. | 광 회절 특성을 갖는 광 투과 영역을 포함하는 광전자 디바이스 |
| US11832473B2 (en) | 2019-06-26 | 2023-11-28 | Oti Lumionics Inc. | Optoelectronic device including light transmissive regions, with light diffraction characteristics |
| US12302691B2 (en) | 2019-08-09 | 2025-05-13 | Oti Lumionics Inc. | Opto-electronic device including an auxiliary electrode and a partition |
| US11737298B2 (en) | 2019-12-24 | 2023-08-22 | Oti Lumionics Inc. | Light emitting device including capping layers on respective emissive regions |
| CN111108860B (zh) * | 2020-01-19 | 2024-05-14 | 黑龙江丰沃非凡农业科技发展有限公司 | 一种仿形播种机 |
| CA3240373A1 (en) | 2020-12-07 | 2022-06-16 | Michael HELANDER | Patterning a conductive deposited layer using a nucleation inhibiting coating and an underlying metallic coating |
| CN117904281B (zh) * | 2024-01-29 | 2024-11-22 | 上海科亦生物科技有限公司 | 检测ugt1a1基因多态性的引物组及试剂盒与方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2020958C (en) * | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| ES2089038T3 (es) * | 1990-01-26 | 1996-10-01 | Abbott Lab | Procedimiento mejorado para amplificar acidos nucleicos blanco aplicable para la reaccion en cadena de polimerasa y ligasa. |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US6228628B1 (en) * | 1997-07-09 | 2001-05-08 | Roche Molecular Systems | Mutant chimeric DNA polymerase |
| US6270973B1 (en) * | 1998-03-13 | 2001-08-07 | Promega Corporation | Multiplex method for nucleic acid detection |
| US6235480B1 (en) * | 1998-03-13 | 2001-05-22 | Promega Corporation | Detection of nucleic acid hybrids |
| US6277578B1 (en) * | 1998-03-13 | 2001-08-21 | Promega Corporation | Deploymerization method for nucleic acid detection of an amplified nucleic acid target |
| US6335162B1 (en) * | 1998-03-13 | 2002-01-01 | Promega Corporation | Nucleic acid detection |
| US6159693A (en) * | 1998-03-13 | 2000-12-12 | Promega Corporation | Nucleic acid detection |
| US6312902B1 (en) * | 1998-03-13 | 2001-11-06 | Promega Corporation | Nucleic acid detection |
| US6391551B1 (en) * | 1998-03-13 | 2002-05-21 | Promega Corporation | Detection of nucleic acid hybrids |
| US6270974B1 (en) * | 1998-03-13 | 2001-08-07 | Promega Corporation | Exogenous nucleic acid detection |
| US7090975B2 (en) | 1998-03-13 | 2006-08-15 | Promega Corporation | Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection |
| US6268146B1 (en) * | 1998-03-13 | 2001-07-31 | Promega Corporation | Analytical methods and materials for nucleic acid detection |
| US6200757B1 (en) * | 1999-01-19 | 2001-03-13 | Dade Behring Inc. | Method for controlling the extension of an oligonucleotide |
| US6509157B1 (en) * | 1999-11-05 | 2003-01-21 | Roche Molecular Systems, Inc | 3 blocked nucleic acid amplification primers |
| WO2001075139A1 (en) * | 2000-04-03 | 2001-10-11 | Biolink Partners, Inc. | Reversible chemical modification of nucleic acids and improved method for nucleic acid hybridization |
-
2001
- 2001-02-22 CA CA2395391A patent/CA2395391C/en not_active Expired - Fee Related
- 2001-02-22 WO PCT/US2001/005527 patent/WO2001062975A2/en not_active Ceased
- 2001-02-22 EP EP01912883A patent/EP1259646B1/en not_active Expired - Lifetime
- 2001-02-22 ES ES01912883T patent/ES2330408T3/es not_active Expired - Lifetime
- 2001-02-22 US US09/789,556 patent/US6534269B2/en not_active Expired - Lifetime
- 2001-02-22 DE DE60139762T patent/DE60139762D1/de not_active Expired - Lifetime
- 2001-02-22 AU AU4162101A patent/AU4162101A/xx active Pending
- 2001-02-22 JP JP2001561783A patent/JP4989004B2/ja not_active Expired - Fee Related
- 2001-02-22 EP EP09166826.9A patent/EP2112233B1/en not_active Expired - Lifetime
- 2001-02-22 AT AT01912883T patent/ATE441726T1/de not_active IP Right Cessation
- 2001-02-22 AU AU2001241621A patent/AU2001241621B2/en not_active Ceased
-
2002
- 2002-10-15 US US10/269,879 patent/US7105298B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001062975A3 (en) | 2002-08-29 |
| CA2395391A1 (en) | 2001-08-30 |
| EP2112233A1 (en) | 2009-10-28 |
| CA2395391C (en) | 2011-08-02 |
| EP1259646A2 (en) | 2002-11-27 |
| US20030092051A1 (en) | 2003-05-15 |
| DE60139762D1 (de) | 2009-10-15 |
| EP2112233B1 (en) | 2013-10-23 |
| US20020127554A1 (en) | 2002-09-12 |
| EP1259646B1 (en) | 2009-09-02 |
| JP4989004B2 (ja) | 2012-08-01 |
| WO2001062975A9 (en) | 2002-10-24 |
| AU4162101A (en) | 2001-09-03 |
| WO2001062975A2 (en) | 2001-08-30 |
| US6534269B2 (en) | 2003-03-18 |
| US7105298B2 (en) | 2006-09-12 |
| ATE441726T1 (de) | 2009-09-15 |
| AU2001241621B2 (en) | 2005-08-25 |
| JP2003526344A (ja) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2330408T3 (es) | Polimerizacion activada por pirofosforolisis (pap): aplicacion en la amplificacion de un alelo especifico y en la determinacion de secuencias de acidos nucleicos. | |
| AU2001241621A1 (en) | Pyrophosphorolysis activated polymerization (PAP): application to allele-specific amplification and nucleic acid sequence determination | |
| US7033763B2 (en) | Pyrophosphorolysis activated polymerization (PAP) | |
| JP5133969B2 (ja) | 加ピロリン酸分解活性化重合（ｐａｐ） | |
| EP1147217B1 (en) | A method of dna sequencing | |
| Liu et al. | Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification | |
| Liu et al. | PAP: detection of ultra rare mutations depends on P* oligonucleotides:“sleeping beauties” awakened by the kiss of pyrophosphorolysis | |
| Kamiya et al. | Induction of mutation of a synthetic c-Ha-ras gene containing hypoxanthine | |
| CA2911712C (en) | Pyrophosphorolysis activated polymerization (pap) | |
| Kabilov et al. | Detection of Three-Nucleotide Deletion ΔF508 in Human Gene CFTR by UV Immobilization on Nylon of a Complex Formed by the PCR-Amplified DNA Fragment with a Highly Specific Probe |